Carbazole and Simplified Derivatives: Novel Tools toward β-Adrenergic Receptors Targeting
Source abstract
Abstract
β-Adrenergic receptors (β-ARs) are G protein-coupled receptors involved in important physiological and pathological processes related to blood pressure and cardiac activity. The inhibition of cardiac β1-ARs could be beneficial in myocardial hypertrophy, ischemia and failure. Several carbazole-based compounds have been described as promising β-blockers. Herein, we investigate the capability of a carbazole derivative and three simplified indole analogs to interact with the active binding site of β1-AR by molecular docking studies. In the light of the obtained results, our compounds were tested by biological assays in H9c2 cardiomyocytes exposed to isoproterenol (ISO) to confirm their potential as β1-blockers agents, and two of them (8 and 10) showed interesting and promising properties. In particular, these compounds were effective against ISO-dependent in vitro cardiac hypertrophy, even at concentrations lower than the known β-AR antagonist propranolol. Overall, the data suggest that the indole derivatives 8 and 10 could act as potent β1-blockers and, active at low doses, could elicit limited side effects.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Receptor Mechanisms and Signaling · Neuropeptides and Animal Physiology · Pharmacological Effects and Assays
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Arcavacata di Rende, Italy
Laboratory of Cellular and Molecular Cardiovascular Pathophysiology, Department of Biology, E and E.S. (DiBEST), University of Calabria, 87036 Arcavacata di Rende, Italy
Department of Health Science, University of Catanzaro Magna Graecia, 88100 Catanzaro, Italy
Department of Pharmacy-Pharmaceutical Sciences, University of Bari Aldo Moro, 70126 Bari, Italy
References (58)
Show source-provided references
1. Three generations of β-blockers: History, class differences and clinical applicability
2. Beta-blockers: Historical Perspective and mechanisms of action10.1016/j.recesp.2019.02.023 ↗
3. On some physiological actions of ergot10.1113/jphysiol.1906.sp001148 ↗
4. G-protein-coupled receptors in heart disease10.1161/CIRCRESAHA.118.311403 ↗
5. Adrenergic blockade of the mammalian heart by a dichloro analogue of isoproterenol
6. Putting theory into practice: James Black, receptor theory and the development of the beta-blockers at ICI, 1958–197810.1017/S0025727300009455 ↗
7. G protein-coupled receptor kinases as therapeutic targets in the heart10.1038/s41569-019-0220-3 ↗
8. Characterisation and expression of β1-, β2- and β3-adrenergic receptors in the fathead minnow (Pimephales promelas)10.1016/j.ygcen.2011.07.006 ↗
9. Cardiac influence of the β3-adrenoceptor in the goldfish (Carassius auratus): A protective role under hypoxia?10.1242/jeb.211334 ↗
10. Exploring cardiac plasticity in teleost: The role of humoral modulation10.1016/j.ygcen.2019.113236 ↗
11. New insights in cardiac β-Adrenergic signaling during heart failure and aging10.3389/fphar.2018.00904 ↗
12. Evolution of β-blockers: From anti-anginal drugs to ligand-directed signalling10.1016/j.tips.2011.02.010 ↗
13. Contemporary use of β-blockers: Clinical relevance of subclassification10.1016/j.cjca.2013.12.001 ↗
14. Isoproterenol-induced hypertrophy of neonatal cardiac myocytes and H9c2 cell is dependent on TRPC3-regulated CaV1.2 expression10.1016/j.ceca.2020.102305 ↗
15. Morphological, biochemical, and electrophysiological characterization of a clonal cell (H9c2) line from rat heart10.1161/01.RES.69.6.1476 ↗
16. Indenopyrazole oxime ethers: Synthesis and β1-adrenergic blocking activity10.1016/j.ejmech.2015.01.037 ↗
17. Quercetin derivatives as novel antihypertensive agents: Synthesis and physiological characterization10.1016/j.ejps.2015.11.021 ↗
18. Chemical and chemoenzymatic routes to 1-(benzothiazol-2-ylsulfanyl)-3-chloropropan-2-ol, a precursor of drugs with potential β-blocker activity10.1016/S0957-4166(00)00102-6 ↗
19. Go, J.G., Santiago, L.D., Miranda, A.C., and Jara, R.D. (2019). Effect of Beta-blockers on Hypertension and Heart Failure with Reduced Ejection Fraction: A Systematic Review of Randomized Controlled Trials. Hypertens. J., 5.10.15713/ins.johtn.0157 ↗
20. The safety of cardio-selective beta1-blockers in asthma: Literature review and search of global pharmacovigilance safety reports10.1183/23120541.00801-2020 ↗
21. Prevention of skin carcinogenesis by the β-blocker carvedilol10.1158/1940-6207.CAPR-14-0193 ↗
22. Binding pathway determines norepinephrine selectivity for the human β1AR over β2AR10.1038/s41422-020-00424-2 ↗
23. Blood pressure lowering efficacy of partial agonist beta blocker monotherapy for primary hypertension
24. Evaluation of intrinsic sympathomimetic activity of bucindolol and carvedilol in rat heart10.1159/000028179 ↗
25. Novel and efficient synthesis of 5,8-dimethyl-9h-carbazol-3-ol via a hydroxydeboronation reaction10.3987/COM-07-11113 ↗
26. Saturnino, C., Grande, F., Aquaro, S., Caruso, A., Iacopetta, D., Bonomo, M., Longo, P., Schols, D., and Sinicropi, M. (2018). Chloro-1,4-dimethyl-9H-carbazole Derivatives Displaying Anti-HIV Activity. Molecules, 23.10.3390/molecules23020286 ↗
27. 3-(Dipropylamino)-5-hydroxybenzofuro[2,3-f]quinazolin-1(2H)-one (DPA-HBFQ-1) plays an inhibitory role on breast cancer cell growth and progression10.1016/j.ejmech.2015.11.004 ↗
28. N-thioalkylcarbazoles derivatives as new anti-proliferative agents: Synthesis, characterisation and molecular mechanism evaluation10.1080/14756366.2017.1419216 ↗
29. A rapid and versatile synthesis of novel pyrimido[5,4-b]carbazoles10.1016/j.tet.2009.10.025 ↗
30. Crystallographic Study and Biological Evaluation of 1,4-dimethyl-N-alkylcarbazoles10.2174/1568026615666150317222444 ↗
31. Avogadro: An advanced semantic chemical editor, visualization, and analysis platform10.1186/1758-2946-4-17 ↗
32. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B ↗
33. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading10.1002/jcc.21334 ↗
34. Grande, F., Rizzuti, B., Occhiuzzi, M.A., Ioele, G., Casacchia, T., Gelmini, F., Guzzi, R., Garofalo, A., and Statti, G. (2018). Identification by molecular docking of homoisoflavones from leopoldia comosa as ligands of estrogen receptors. Molecules, 23.10.3390/molecules23040894 ↗
35. A pilot study on the nutraceutical properties of the Citrus hybrid Tacle® as a dietary source of polyphenols for supplementation in metabolic disorders10.1016/j.jff.2018.11.030 ↗
36. The chromogranin A1-373 fragment reveals how a single change in the protein sequence exerts strong cardioregulatory effects by engaging neuropilin-110.1111/apha.13570 ↗
37. Notch1 mediates preconditioning protection induced by gper in normotensive and hypertensive female rat hearts10.3389/fphys.2018.00521 ↗
38. Quercetin and its derivative Q2 modulate chromatin dynamics in adipogenesis and Q2 prevents obesity and metabolic disorders in rats10.1016/j.jnutbio.2019.03.019 ↗
39. Cateslytin abrogates lipopolysaccharide-induced cardiomyocyte injury by reducing inflammation and oxidative stress through toll like receptor 4 interaction10.1016/j.intimp.2021.107487 ↗
40. Protective role for LPA3 in cardiac hypertrophy induced by myocardial infarction but not by isoproterenol10.3389/fphys.2017.00356 ↗
41. Synthesis, inhibition of NO production and antiproliferative activities of some indole derivatives10.1080/14756360802693890 ↗
42. A synthesis of ellipticine10.1039/jr9620003482 ↗
43. Étude de la cytotoxicitéin vitro de dérivés du carbazole III. 3-Amino et 3-nitro-1,4-diméthyl-9H-carbazoles diversement substitués en position10.1016/0223-5234(90)90197-B ↗
44. Cytotoxic potential of novel 6,7-dimethoxyquinazolines10.1016/j.ejmech.2011.12.020 ↗
45. Antiproliferative activity of some 1,4-dimethylcarbazoles on cells that express estrogen receptors: Part I10.3109/14756366.2011.603132 ↗
46. Adrenergic nervous system in heart failure: Pathophysiology and therapy10.1161/CIRCRESAHA.113.300308 ↗
47. Myocardial oxidative stress contributes to transgenic β 2- adrenoceptor activation-induced cardiomyopathy and heart failure10.1111/j.1476-5381.2010.01043.x ↗
48. β-adrenergic cardiac hypertrophy is mediated primarily by the β1-subtype in the rat heart10.1006/jmcc.2000.1332 ↗
49. Regulation of β-adrenoceptor density and mRNA levels in the rat heart cell-line H9c10.1042/bj3170925 ↗
50. What is the role of β-adrenergic signaling in heart failure?10.1161/01.RES.0000102042.83024.CA ↗
51. β-Adrenergic receptor stimulation causes cardiac hypertrophy via a Gβγ/Erk-dependent pathway10.1093/cvr/cvs249 ↗
52. Comparative pharmacology of human β-adrenergic receptor subtypes-characterization of stably transfected receptors in CHO cells10.1007/s00210-003-0860-y ↗
53. Mutations inducing divergent shifts of constitutive activity reveal different modes of binding among catecholamine analogues to the β2-adrenergic receptor10.1038/sj.bjp.0704622 ↗
54. Titration of β-blockers in heart failure: How to maximize benefit while minimizing adverse events10.3810/pgm.2003.03.1389 ↗
55. Call for papers impact of sympathoexcitation on cardiovascular function in humans effects of incremental beta-blocker dosing on myocardial mechanics of the human left ventricle: MRI 3D-tagging insight into pharmacodynamics supports theory of inner antagonism10.1152/ajpheart.00746.2014 ↗
56. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction10.1093/eurheartj/ehi705 ↗
57. Low drug doses may improve outcomes in chronic disease10.5694/j.1326-5377.2009.tb02916.x ↗
58. β-adrenoceptor blockers valuable but higher doses not necessary10.1111/bcp.12439 ↗